Splicing-mediated control of hnRNPD isoform switching by SRSF2 drives PD-L1-dependent immune evasion in gallbladder cancer.
RNA splicing machinery controls immune checkpoint expression in gallbladder cancer, suggesting new treatment combination possibilities.
This mechanistic Oncogene study identified an SRSF2-driven hnRNPD isoform switch that upregulates PD-L1 in gallbladder cancer, enabling tumor immune evasion through a novel RNA splicing-immune checkpoint axis. Findings provide mechanistic rationale for targeting RNA splicing factors in combination with anti-PD-L1 immunotherapy in gallbladder and biliary tract cancers.
What the study was
- Study design
- Experimental mechanistic study (in vitro and in vivo)
- Category
- Other
- Maturity
- Exploratory
- Journal
- Oncogene
Why it surfaced
Oncogene publication; novel splicing-immune evasion mechanism in gallbladder cancer (limited immunotherapy data); provides mechanistic basis for checkpoint inhibitor combination strategies in biliary tract malignancies.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.